The RANKL: Osteoprotegerin (OPG) ratio as a new biomarker for coronary artery disease

Iranian Journal of Medical Hypotheses and Ideas

Volumn 3, Issue 1, 2009, Pages

  Shamsara, Jamal ^a   Ramezani, Mohammad ^a   Mohammadpour, Amir Hoosang ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Osteoprotegerin; RANKL

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; BINDING COMPETITION; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CORONARY ARTERY DISEASE; HUMAN; IN VITRO STUDY; INFLAMMATION; NONHUMAN; OSTEOLYSIS; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

EID: 77953434455     PISSN: 17359104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hellings, W.E., W. Peeters, F.L. Moll, and G. Pasterkamp, From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc Med 2007;17(5):162-171.
2. Naghavi, M., P. Libby, E. Falk, S.W. Casscells, S. Litovsky, J. Rumberger, J.J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, Z. Fayad, P.H. Stone, S. Waxman, P. Raggi, M. Madjid, A. Zarrabi, A. Burke, C. Yuan, P.J. Fitzgerald, D.S. Siscovick, C.L. de Korte, M. Aikawa, K.E. Juhani Airaksinen, G. Assmann, C.R. Becker, J.H. Chesebro, A. Farb, Z.S. Galis, C. Jackson, I.K. Jang, W. Koenig, R.A. Lodder, K. March, J. Demirovic, M. Navab, S.G. Priori, M.D. Rekhter, R. Bahr, S.M. Grundy, R. Mehran, A. Colombo, E. Boerwinkle, C. Ballantyne, W. Insull, Jr., R.S. Schwartz, R. Vogel, P.W. Serruys, G.K. Hansson, D.P. Faxon, S. Kaul, H. Drexler, P. Greenland, J.E. Muller, R. Virmani, P.M. Ridker, D.P. Zipes, P.K. Shah, and J.T. Willerson, From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003;108(14):1664-1672.
3. Kolodgie, F.D., R. Virmani, A.P. Burke, A. Farb, D.K. Weber, R. Kutys, A.V. Finn, and H.K. Gold, Pathologic assessment of the vulnerable human coronary plaque. Heart 2004;90(12):1385-1391.
4. Boyce, B.F. and L. Xing, Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007;9 Suppl 1:S1.
5. Schoppet, M., K.T. Preissner, and L.C. Hofbauer, RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22(4):549-553.
6. Collin-Osdoby, P., Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95(11):1046-1057.
7. Ketteler, M., R. Westenfeld, G. Schlieper, V. Brandenburg, and J. Floege, "Missing" inhibitors of calcification: general aspects and implications in renal failure. Pediatr Nephrol 2005;20(3):383-388.
8. Wallin, R., N. Wajih, G.T. Greenwood, and D.C. Sane, Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001;21(4):274-301.
9. Abedin, M., Y. Tintut, and L.L. Demer, Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24(7):1161-1170.
10. Hofbauer, L.C., C.C. Brueck, C.M. Shanahan, M. Schoppet, and H. Dobnig, Vascular calcification and osteoporosis - from clinical observation towards molecular understanding. Osteoporos Int 2007;18(3):251-259.
11. Ketteler, M. and C. Giachelli, Novel insights into vascular calcification. Kidney Int Suppl 2006;(105):S5-S9.
12. Kiechl, S., G. Schett, J. Schwaiger, K. Seppi, P. Eder, G. Egger, P. Santer, A. Mayr, Q. Xu, and J. Willeit, Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007;116(4):385-391.
13. Bennett, B.J., M. Scatena, E.A. Kirk, M. Rattazzi, R.M. Varon, M. Averill, S.M. Schwartz, C.M. Giachelli, and M.E. Rosenfeld, Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol 2006;26(9):2117-2124.
14. Vik, A., E.B. Mathiesen, A.T. Noto, B. Sveinbjornsson, J. Brox, and J.B. Hansen, Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 2007;191(1):128-134.
15. Dhore, C.R., J.P. Cleutjens, E. Lutgens, K.B. Cleutjens, P.P. Geusens, P.J. Kitslaar, J.H. Tordoir, H.M. Spronk, C. Vermeer, and M.J. Daemen, Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21(12):1998-2003.
16. Anand, D.V., E. Lim, D. Darko, P. Bassett, D. Hopkins, D. Lipkin, R. Corder, and A. Lahiri, Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 2007;50(23):2218-2225.
17. Schoppet, M., A.M. Sattler, J.R. Schaefer, M. Herzum, B. Maisch, and L.C. Hofbauer, Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003;88(3):1024-1028.
18. Schoppet, M., N. Al-Fakhri, F.E. Franke, N. Katz, P.J. Barth, B. Maisch, K.T. Preissner, and L.C. Hofbauer, Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004;89(8):4104-4112.
19. Golledge, J., M. McCann, S. Mangan, A. Lam, and M. Karan, Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004;35(7):1636-1641.
20. Kiechl, S., G. Schett, G. Wenning, K. Redlich, M. Oberhollenzer, A. Mayr, P. Santer, J. Smolen, W. Poewe, and J. Willeit, Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109(18):2175-2180.
21. Avignon, A., A. Sultan, C. Piot, S. Elaerts, J.P. Cristol, and A.M. Dupuy, Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005;28(9):2176-2180.
22. Ueland, T., R. Jemtland, K. Godang, J. Kjekshus, A. Hognestad, T. Omland, I.B. Squire, L. Gullestad, J. Bollerslev, K. Dickstein, and P. Aukrust, Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004;44(10):1970-1976.
23. Abedin, M., T. Omland, T. Ueland, A. Khera, P. Aukrust, S.A. Murphy, T. Jain, U. Gruntmanis, D.K. McGuire, and J.A. de Lemos, Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007;99(4):513-518.
24. Anand, D.V., A. Lahiri, E. Lim, D. Hopkins, and R. Corder, The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47(9):1850-1857.
25. Guldiken, B., S. Guldiken, B. Turgut, N. Turgut, M. Demir, Y. Celik, E. Arikan, and A. Tugrul, Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 2007;120(4):511-516.
26. Rhee, E.J., W.Y. Lee, S.Y. Kim, B.J. Kim, K.C. Sung, B.S. Kim, J.H. Kang, K.W. Oh, E.S. Oh, K.H. Baek, M.I. Kang, H.Y. Woo, H.S. Park, S.W. Kim, M.H. Lee, and J.R. Park, Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 2005;108(3):237-243.
27. Bargnoux, A.S., A.M. Dupuy, V. Garrigue, S. Deleuze, J.P. Cristol, and G. Mourad, Renal transplantation decreases osteoprotegerin levels. Transplant Proc 2006;38(7):2317-2318.
28. Crisafulli, A., A. Micari, D. Altavilla, F. Saporito, A. Sardella, M. Passaniti, S. Raffa, G. D'Anneo, F. Luca, C. Mioni, F. Arrigo, and F. Squadrito, Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 2005;109(4):389-395.
29. Asanuma, Y., C.P. Chung, A. Oeser, J.F. Solus, I. Avalos, T. Gebretsadik, A. Shintani, P. Raggi, T. Sokka, T. Pincus, and C.M. Stein, Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 2007;195(2):e135-e141.
30. Sandberg, W.J., A. Yndestad, E. Oie, C. Smith, T. Ueland, O. Ovchinnikova, A.K. Robertson, F. Muller, A.G. Semb, H. Scholz, A.K. Andreassen, L. Gullestad, J.K. Damas, S.S. Froland, G.K. Hansson, B. Halvorsen, and P. Aukrust, Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006;26(4):857-863.
31. Grimaud, E., L. Soubigou, S. Couillaud, P. Coipeau, A. Moreau, N. Passuti, F. Gouin, F. Redini, and D. Heymann, Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 2003;163(5):2021-2031.
32. Rouster-Stevens, K.A., C.B. Langman, H.E. Price, R. Seshadri, R.M. Shore, K. Abbott, and L.M. Pachman, RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 2007;56(3):977-983.
33. Geusens, P.P., R.B. Landewe, P. Garnero, D. Chen, C.R. Dunstan, W.F. Lems, P. Stinissen, D.M. van der Heijde, S. van der Linden, and M. Boers, The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54(6):1772-1777.
34. Libby, P., P.M. Ridker, and A. Maseri, Inflammation and atherosclerosis. Circulation 2002;105(9):1135-11343.
35. Zaninotto, M., M.M. Mion, E. Novello, S. Altinier, and M. Plebani, New biochemical markers: from bench to bedside. Clin Chim Acta 2007;381(1):14-20.
36. Kullo, I.J. and C.M. Ballantyne, Conditional risk factors for atherosclerosis. Mayo Clin Proc 2005;80(2):219-230.
37. Sattler, A.M., M. Schoppet, J.R. Schaefer, and L.C. Hofbauer, Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004;74(1):103-106.